Juliet Preston is a freelance writer based in San Diego.
T2 Biosystems’ novel MRI-based platform for diagnosing invasive candida infections is fast and accurate. Does that automatically translate to lower hospital costs?
The system has an artificial intelligence algorithm that evaluates the images coming from the camera and determines whether or not there's diabetic retinopathy in them,” explained IDx Founder and President Michael Abràmoff. “So it makes a clinical decision, without someone like me being involved — it's fully autonomous.”
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Y Combinator graduate Zenflow has raised a $31.4 million Series A following a successful human trial of its Spring System in patients with benign prostatic hyperplasia (BPH) or enlarged prostate.
Avrobio has secured $60 million in new financing on the back of its first successful gene therapy trial in a patient with Fabry disease.
vTv Therapeutics has spent nearly two decades advancing its Alzheimer’s drug, and results from two Phase 3 trials are expected in 2018.
Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage assets. Less than one month in, the predictions seem to be coming true.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Oncology has long been borrowing lessons from immunology. It may now be time to pay it back. Pandion Therapeutics is tapping into some immune evasion tools observed in cancer to better treat autoimmune and inflammatory disorders.
There’s a giant talent void hitting the life sciences and there won't be enough white men to fill that gap as baby boomers retire in droves.
Pinpointing the expiration date of drug patents can make filing taxes look like child's play. Each drug has wide ranging intellectual property, with timelines that are ever-changing. That said, here’s a list of 26 drugs that will probably go off patent in 2018.
With the tax reform bill that recently passed and the dramatic rate-cut for overseas cash being repatriated to 14.5 percent from 35 percent, it's no surprise that M&A deals will abound.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.
San Diego, California-based Genalyte has spent 10 years developing its lab-on-a-chip technology. Now it’s ready, to try it out on J.P. Morgan investors, quite literally.
The J.P. Morgan Healthcare Conference is about so much more than the company presentations. Partnerships are made, deals are signed, and the tone for the biopharma year ahead is set. Or is it?
Pfizer is paying big bucks for yet-to-be-discovered small molecule drugs that can break down harmful proteins in diseases such as cancer and Alzheimer’s.
2017 was a blockbuster year for drug approvals, with 46 new molecular entities and some first-of-their-kind gene therapies given the green light. But how much will the new drugs add to the medical armamentarium? And at what cost?